SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device. JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the […]
Medtronic
Medtronic touts therapy delivered via SynchroMed pump in patients with post-stroke spasticity
Medtronic (NYSE:MDT) touted data today showing that intrathecal baclofen therapy delivered via the company’s SychroMed II infusion pump performed better than the conventional treatment for patients with severe post-stroke spasticity. The medtech titan’s SynchroMed II pump is the only device approved in the U.S. for ITB therapy. The Sisters study pitted Medtronic’s ITB therapy against oral […]
Svelte Medical launches pivotal trial for drug-eluting stent-on-a-wire
The first patient has been enrolled in Svelte Medical System‘s Optimize pivotal trial, which is designed to evaluate the safety and efficacy of Svelte’s drug-eluting stent integrated delivery system and rapid exchange platforms. The 2,000-person trial comes in the wake of a first-in-man trial for Svelte’s product and a study comparing the system with Medtronic‘s […]
FDA approves clinician app for Medtronic’s SynchroMed II drug pump
The FDA has approved a new clinician application for Medtronic‘s (NYSE:MDT) SynchroMed II intrathecal drug pump. The newly-approved programmer was designed to give doctors visual tools and improved workflows to simplify therapy management. The medtech titan’s implantable pump, which has been problematic in the past, delivers drugs directly to the fluid around the spinal cord. […]
The ‘smart pill’ market could be worth $3B by 2025 – meet the key players
The “smart pill” market is expected to nearly quadruple in value to $3 billion by 2025, according to Grand View Research. Driving this growth is an increasing demand for minimally-invasive procedures, as well as better patient monitoring capabilities. There are a number of players in the pharmaceutical and medtech arenas looking to stake a claim […]
Semma Therapeutics closes $114m round to advance cell therapy for Type I diabetes
Semma Therapeutics has closed an oversubscribed $114 million Series B round to help fund the development of its encapsulated stem cell-derived islet therapy for Type I diabetes. The Cambridge, Mass.-based company reported that it plans to use the newly-acquired funds to bring its cell therapy through clinical proof-of-concept studies, as well as explore other regenerative […]
Medtronic retools SynchroMed II infusion pump
Medtronic (NYSE:MDT) said this month that it won approval for a change to its problematic SynchroMed II implantable drug infusion pump designed to address motor shaft wear issues. The Fridley, Minn.-based medical device titan said the change is aimed at improving the long-term rate of non-recoverable motor stall in the SynchroMed II devices, estimating that pump […]
JDRF touts win after Anthem decides to cover artificial pancreas systems
JDRF said today it successfully persuaded Anthem to cover artificial pancreas systems, after meeting the health insurer as part of its Coverage2Control campaign. America’s 25 largest health insurers now cover Medtronic‘s (NYSE:MDT) MiniMed system, according to the organization. “This is a great victory for the T1D community. By taking this tremendous step, Anthem is giving […]
How DarioHealth turned the smartphone into a user-friendly glucose monitor
When DarioHealth (NSDQ:DRIO) CEO Erez Raphael looks at the medical device world, he sees solutions that were designed by healthcare professionals and doctors – and this presents a stark contrast with the consumer device industry, he pointed out. “We have seen there are a lot of cases, most of the cases in the industry, where the […]
TCT 2017: Medtronic & OrbusNeich evaluate shortening dual anti-platelet therapy with drug-eluting stents
At this year’s Transcatheter Cardiovascular Therapeutics meeting, companies presented work comparing shortened durations of dual anti-platelet therapy with the standard 1-year regimen in patients treated with a drug-eluting stent. Among those companies were Medtronic (NYSE:MDT) and OrbusNeich. Here’s a look at what they found. Medtronic’s DAPT-STEMI trial Yesterday, investigators presented data from Medtronic’s independently-run DAPT-STEMI trial, […]